Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1Anemia, Aplastic 1Anemia 1

Interventions

Cyclophosphamide 50fludarabine phosphate 47Busulfan 46Cyclosporine 36Antilymphocyte Serum 33Cytarabine 32Peripheral Blood Stem Cell Transplantation 30Radiotherapy 28Filgrastim 27Methotrexate 23Melphalan 23Mycophenolic Acid 21Cord Blood Stem Cell Transplantation 21Methylprednisolone 20Etoposide 17Whole-Body Irradiation 16Tacrolimus 15Daunorubicin 11Epoetin Alfa 10fludarabine 9Thiotepa 9Alemtuzumab 8Idarubicin 7Granulocyte Colony-Stimulating Factor 7sargramostim 6Topotecan 6Mitoxantrone 6Azacitidine 6Arsenic Trioxide 6Gemtuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Immunosuppression Therapy × Classical hematology × Clear all
NCT00987480 2018-07-10

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
45 enrolled 12 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Anemia, Aplastic, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡